TY - JOUR
T1 - Latest developments in chronic total occlusion percutaneous coronary intervention
AU - Nikolakopoulos, Ilias
AU - Vemmou, Evangelia
AU - Karacsonyi, Judit
AU - Xenogiannis, Iosif
AU - Werner, Gerald S.
AU - Gershlick, Anthony H.
AU - Rinfret, Stephane
AU - Yamane, Masahisa
AU - Avran, Alexandre
AU - Egred, Mohaned
AU - Garcia, Santiago
AU - Burke, M. Nicholas
AU - Brilakis, Emmanouil S.
N1 - Funding Information:
AH Gershlick received travel sponsorship and speaker’s fees from Abbott Vascular and Medtronic. S Rinfret received consultant honoraria from Boston Scientific, Teleflex, Abbott Vascular, Abiomed, and SoundBite Medical. A Avran received proctoring income from Boston Scientific, Abbott Vascular, Terumo, Biotronik, and Biosensors. M Egred received proctor income for ELCA, honoraria and speaker fees from Philips, Abbott Vascular, Boston Scientific, Vascular Perspectives, Biosensors, Biotronik, and AstraZeneca. S Garcia received consulting fees from Medtronic. MN Burke received consulting and speaker honoraria from Abbott Vascular and Boston Scientific. ES Brilakis received consulting/speaker honoraria from Abbott Vascular, American Heart Association (associate editor Circulation), Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), CSI, Elsevier, GE Healthcare, InfraRedx, Medtronic, Siemens, and Teleflex; research support from Regeneron and Siemens. Shareholder: MHI Ventures. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020
Y1 - 2020
N2 - Introduction: Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) is now performed with high success rates and acceptable complication rates. Areas covered: We describe recent clinical and technological developments in CTO PCI from 2018 to 2020. Expert opinion: After publication of six randomized controlled trials, improving patient symptoms remains the principal indication for CTO PCI. Although good outcomes can be achieved with CTO PCI at experienced centers, success rates are significantly lower at less experienced centers, despite increased use in CTO crossing algorithms and development of novel and improved equipment and techniques.
AB - Introduction: Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI) is now performed with high success rates and acceptable complication rates. Areas covered: We describe recent clinical and technological developments in CTO PCI from 2018 to 2020. Expert opinion: After publication of six randomized controlled trials, improving patient symptoms remains the principal indication for CTO PCI. Although good outcomes can be achieved with CTO PCI at experienced centers, success rates are significantly lower at less experienced centers, despite increased use in CTO crossing algorithms and development of novel and improved equipment and techniques.
KW - Chronic total occlusion
KW - coronary artery disease
KW - coronary occlusion percutaneous coronary intervention
KW - stent
UR - http://www.scopus.com/inward/record.url?scp=85087979257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087979257&partnerID=8YFLogxK
U2 - 10.1080/14779072.2020.1787153
DO - 10.1080/14779072.2020.1787153
M3 - Review article
C2 - 32594784
AN - SCOPUS:85087979257
SP - 415
EP - 426
JO - Expert Review of Cardiovascular Therapy
JF - Expert Review of Cardiovascular Therapy
SN - 1477-9072
ER -